2025中国手术机器人获批年报

Core Viewpoint - The article provides a comprehensive overview of the approval status of surgical robots in China for the year 2025, highlighting the concentration of approvals in specific categories and the steady pace of regulatory processes throughout the year [2][5][9]. Summary by Sections 1. Approval by Category - The approval of surgical robots in 2025 shows a highly concentrated structure, with orthopedic surgical robots leading in the number of approvals, significantly surpassing other categories. Other categories such as puncture, endoscopic, and natural orifice approaches are in the second tier with single-digit approvals. Vascular intervention and neurosurgery products have relatively few approvals, indicating they are still in early development stages [5][9][10]. 2. Approval by Time - The distribution of approvals throughout 2025 indicates a stable and uniform rhythm, with no significant concentration in any single quarter or short-term window. Monthly fluctuations in approval numbers were minor, suggesting a normalization of the approval process rather than a surge driven by specific policy changes or concentrated applications [7][10][12]. 3. Annual Trend Assessment - The overall characteristics of surgical robot approvals in 2025 can be summarized as follows: - The number of approvals has maintained a steady pace without significant acceleration or inflection points, indicating a trend towards stable output rather than rapid expansion [10][11]. - The structural differentiation among categories is clear, with orthopedic products continuing to dominate the approvals [11][12]. - The approval rhythm has normalized, focusing more on specific products and application scenarios rather than short-term bursts of activity [12].